Aboelsaad, I.; Ashmawy, R.; Mahrous, D.; Sharaf, S.; Aly, S.; Abdullatif, S.; Fakhry, A.; Hassan, B.; Khamis, D.; Aldakhs, A.;
et al. Clinical Outcomes and Survival Analysis of Remdesivir as a Treatment Option for Moderate to Severe COVID-19 Patients. COVID 2022, 2, 1758-1767.
https://doi.org/10.3390/covid2120126
AMA Style
Aboelsaad I, Ashmawy R, Mahrous D, Sharaf S, Aly S, Abdullatif S, Fakhry A, Hassan B, Khamis D, Aldakhs A,
et al. Clinical Outcomes and Survival Analysis of Remdesivir as a Treatment Option for Moderate to Severe COVID-19 Patients. COVID. 2022; 2(12):1758-1767.
https://doi.org/10.3390/covid2120126
Chicago/Turabian Style
Aboelsaad, Iman, Rasha Ashmawy, Doaa Mahrous, Sandy Sharaf, Shahinda Aly, Sara Abdullatif, Ayat Fakhry, Basma Hassan, Dalia Khamis, Alaa Aldakhs,
and et al. 2022. "Clinical Outcomes and Survival Analysis of Remdesivir as a Treatment Option for Moderate to Severe COVID-19 Patients" COVID 2, no. 12: 1758-1767.
https://doi.org/10.3390/covid2120126
APA Style
Aboelsaad, I., Ashmawy, R., Mahrous, D., Sharaf, S., Aly, S., Abdullatif, S., Fakhry, A., Hassan, B., Khamis, D., Aldakhs, A., & Kamal, E.
(2022). Clinical Outcomes and Survival Analysis of Remdesivir as a Treatment Option for Moderate to Severe COVID-19 Patients. COVID, 2(12), 1758-1767.
https://doi.org/10.3390/covid2120126